GSA Capital Partners’s Verona Pharma VRNA Stock Holding History

GSA Capital Partners’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,198	Closed	-$1.2M	–	2123
2025 Q3	$1.2M	Buy	11,198 +3,895	+53%	+$407K	0.1%	294
2025 Q2	$691K	Sell	7,303 -13,223	-64%	-$979K	0.05%	698
2025 Q1	$1.3M	Sell	20,526 -32,846	-62%	-$1.96M	0.12%	227
2024 Q4	$2.48M	Buy	53,372 +23,859	+81%	+$896K	0.18%	49
2024 Q3	$849K	Buy	+29,513	New	+$726K	0.06%	578
2023 Q3	–	Sell	-29,432	Closed	-$622K	–	1942
2023 Q2	$622K	Buy	+29,432	New	+$628K	0.06%	604
2022 Q2	–	Sell	-13,150	Closed	-$66K	–	1832
2022 Q1	$66K	Buy	+13,150	New	+$76.5K	0.01%	1329

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

GSA Capital Partners's VRNA Position: Q4 2025 in Review

GSA Capital Partners sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 11,198 shares — an estimated $1.2M sold.

GSA Capital Partners first reported a position in VRNA in Q1 2022 and held it in 7 quarters. The position peaked at $2.48M in Q4 2024. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

GSA Capital Partners reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
GSA Capital Partners sold 11,198 Verona Pharma shares in Q4 2025, an estimated $1.2M.
GSA Capital Partners first reported a position in Verona Pharma in Q1 2022 and held it in 7 quarters.
GSA Capital Partners's Verona Pharma position peaked at $2.48M in Q4 2024.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.